Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) in Healthy Adults

A Single-arm, Open-label, Single-center, Phase 1 Study to Investigate the Safety and Efficacy of GC3107 (BCG Vaccine) After Intradermal Administration in Healthy Adults

Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally.

Healthy adults will be once administered GC3107(BCG Vaccine) Intradermally. Tuberculin Skin Test(TST) will be conducted after 84+7 days after IP injection and TST result will be read in 48~72 hours.

Inclusion Criteria:

• Healthy adults aged 19-64 years old
• Informed consent form has been signed and dated
• Able to comply with the requirements of the study
• Female subjects who have negative results in Urine hCG test at screening, or menopausal women.

Exclusion Criteria:

• Subjects who have positive results(;induration diameter over 5mm) in Tuberculin Skin Test(TST) at screening
• Subjects who shown abnormal results(including inactive tuberculosis) on Chest X-ray at screening
• Subjects who received a vaccination(including live vaccine) within 28 days before enrollment
• Subjects who are on antituberculosis drugs
• Immunocompromised subjects with immunodeficiency disease or subjects receiving immunosuppressive or immunomodulating therapy
• Subjects with severe chronic disease who are considered by investigator to be ineligible for the study
• Pregant or lactating women